NASDAQ · ELUT
Elutia Inc
$0.80-$0.01 (-1.24%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
Loading market information…
NASDAQ · RNLX · USD
Stock price, earnings
Quote as of Oct 7, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Renalytix Plc’s quoted price sits in the lower half of its reported 52-week range, 91.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Renalytix Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:30 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Jun 9, 2023 | -$0.130.0% vs estimate | $724.00K-51.08% vs estimate |
|---|
| Q2 2023 | Mar 30, 2023 | -$0.14+6.67% vs estimate | $1.19M-7.12% vs estimate |
|---|
KEEP COMPARING
$0.80-$0.01 (-1.24%)
Elutia Inc’s quoted price sits in the lower half of its reported 52-week range, 42.19% below the high.
$0.66$0.00 (0.0%)
Invacare Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.92% below the high.
$0.72$0.00 (0.0%)
Cyclo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.52% below the high.
$5.33$0.00 (0.0%)
Streamline Health Solutions, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.56% below the high.
$0.37-$0.01 (-2.12%)
Elevation Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.19% below the high.
$3.07+$0.29 (+10.43%)
MEI Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.89% below the high.
$2.27+$0.01 (+0.44%)
Conformis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$1.24+$0.05 (+4.16%)
MetaVia Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.65% below the high.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
